New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
06:33 EDTONCYOncolytics Biotech collaborators present head, neck cancer biomarker poster
Oncolytics Biotech announced that a poster authored by Bolton, et al was presented at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Resistance to oncolytic reovirus is associated with high expression of Yes-Associated Protein, or YAP-1, in head and neck cancer," covered preclinical research focused on identifying biomarkers predictive of sensitivity/resistance to reovirus in head and neck cancer cell lines. Researchers examined reovirus in panels of head and neck cancer cell lines to determine their sensitivity to reovirus-induced oncolysis. The study results showed that high YAP-1 protein expression correlated with reovirus resistance, whereas low YAP-1 expression correlated with sensitivity to reovirus infection. They also indicated that knocking the YAP-1 gene down resulted in certain cells becoming significantly more sensitive to reovirus infection. The researchers concluded that YAP-1 is a possible biomarker for sensitivity/resistance to reovirus infection in head and neck cancer and that further investigation into the crosstalk between chemical signaling pathways upstream and downstream of YAP-1 and its cellular localization, is important in understanding how it may be impeding reovirus oncolysis.
News For ONCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
06:33 EDTONCYOncolytics Biotech's Reolysin shows positive preclinical results in melanoma
Oncolytics Biotech announced an oral presentation by the company's research collaborators from a variety of melanoma models. They concluded that the combination of Reolysin and radiation therapy enhances cytotoxicity in those cell lines by increasing programmed cancer cell death, and that radiation therapy supports increased reovirus replication and suppresses the host cell's anti-viral defenses. This builds on a recent publication that demonstrated that Reolysin could act synergistically in combination with a new class of targeted agents to treat skin cancers with a specific mutation. The publication outlined how the combination of REolysin and BRAF inhibitors improved survival in mouse models compared to either agent alone.
March 3, 2015
06:34 EDTONCYOncolytics Biotech receives ODD from FDA for Reolysin
Oncolytics Biotech announced that the FDA has granted Orphan Drug Designation, or ODD, for its lead product candidate, Reolysin, for the treatment of primary peritoneal cancers. The designation was granted on the basis of the Company's December 2014 application for an Orphan Drug Designation encompassing ovarian, fallopian tube and primary peritoneal cancers which are generally treated as one indication. On February 11, the company announced that it had received Orphan Drug Designation for ovarian cancer and for cancers of the fallopian tube on March 2.
06:32 EDTONCYOncolytics Biotech receives Orphan Drug Designation for Reolisyn
Oncolytics Biotech announced that the FDA has granted Orphan Drug Designation for its lead product candidate, Reolisyn, for the treatment of primary peritoneal cancers. The designation was granted on the basis of the Company's December 2014 application for an Orphan Drug Designation encompassing ovarian, fallopian tube and primary peritoneal cancers which are generally treated as one indication.
March 2, 2015
06:38 EDTONCYOncolytics Biotech announces receipt of Orphan Drug Designatoin for REOLYSIN
Subscribe for More Information
06:37 EDTONCYOncolytics Biotech receives ODD from FDA for Reolysin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use